Vernalis Forum

For those seeking some detailed insight on Vernalis, here's a recent report (pre-dates the 6 Mar Announcement on Servier collaboration):

[link]

Read Edison's note on Vernalis, out this morning on Research Tree: "The issue of 80m new shares at 50p/share has raised £40m (gross), which enables Vernalis to focus on executing its operational plan and removes uncertainty over whether it is sufficiently funded through to sustainable profitability in FY19 (on our new forecasts). Near-term investment into the commercial cough cold platform will underpin future sales growth. Ongoing initiatives to improve physician awareness, stocking and formulary coverage should increase Tuzistra’s XR market share in the longer term..."

Welcome to the new Vernalis stream forum! Messages posted in the Vernalis stream will be logged here for posterity.

RNS: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept. Expected but good to see another one going through, augurs well for the rst of the development pipeline. Getting nearer to commercialiasation when it will be possible to put a more precise valuation on the business. NB Neil Woodford owns 6.7% in his new fund.